Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04458259 · ClinicalTrials.gov registry record · Phase 1
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
NCT04458259 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 88 participants.
The verdict
NCT04458259, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
Study Summary
A First-in-Human Pharmacokinetic, Safety, and Tolerability Study of PF-07265807 as Monotherapy and in Combination in Participants with Advanced or Metastatic Solid Tumors
Interventions
- DRUG Axitinib
- DRUG Sasanlimab
- DRUG PF-07265807
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2020-09-24 |
| Est. Completion | 2024-11-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04458259
The ClinicalTrials.gov registry entry for NCT04458259 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Axitinib is the first listed.
NCT04458259 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04458259 about?
NCT04458259 is a clinical study titled "Study of PF-07265807 in Participants With Metastatic Solid Tumors.". A First-in-Human Pharmacokinetic, Safety, and Tolerability Study of PF-07265807 as Monotherapy and in Combination in Participants with Advanced or Metastatic Solid Tumors
What is the current status of trial NCT04458259?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2020-09-24. Estimated completion is 2024-11-15.
What interventions are being tested in trial NCT04458259?
The interventions under investigation include: Axitinib (DRUG), Sasanlimab (DRUG), PF-07265807 (DRUG).
Who is sponsoring clinical trial NCT04458259?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.